Clinical effect of Jinlong capsules combined with Western medicine treatment in treatment of primary liver cancer: A Meta-analysis
- VernacularTitle:金龙胶囊联合西医疗法治疗原发性肝癌效果的Meta分析
- Author:
SHI Ke
1
Author Information
- Publication Type:Journal Article
- Keywords: liver neoplasms; Jinlong capsules; integrated TCM WM; treatment outcome； Meta-analysis
- From: Journal of Clinical Hepatology 2019;35(11):2495-2501
- CountryChina
- Language:Chinese
- Abstract: ObjectiveTo investigate the clinical effect and adverse events of Jinlong capsules combined with Western medicine treatment in the treatment of advanced primary liver cancer. MethodsPubMed, The Cochrane library, CNKI, Wanfang Data, CBM, and VIP were searched for randomized controlled trials (RCTs) on Jinlong capsules combined with Western medicine treatment in the treatment of advanced primary liver cancer published up to May 2019. The patients treated with Jinlong capsules combined with Western medicine treatment were enrolled as intervention group, and those treated with Western medicine treatment alone were enrolled as control group. Data extraction and quality assessment were performed, and RevMan 5.3 was used to perform the Meta-analysis with a fixed or random effects model. ResultsA total of 26 RCTs were included, with a total of 2318 patients (1175 patients in the intervention group and 1143 patients in the control group). The results of the Meta-analysis showed that compared with Western medicine treatment alone, Jinlong capsules combined with Western medicine treatment had significant increases in response rate (relative risk ［RR］=1.36, 95% confidence interval ［CI］: 125-1.49, P＜0.001), 1-year survival rate (RR=1.29, 95%CI: 1.14-1.47, P＜0.001), Karnofsky Performance Scale score (RR=137, 95%CI: 1.19-1.59, P＜0.001), peripheral blood CD3+ T lymphocytes (mean difference ［MD］=11.18, 95%CI: 268-1968, P=0.01), CD4+ T lymphocytes (MD=6.43, 95%CI: 3.82-9.05, P＜0.001), and CD4+/CD8+ ratio (MD=0.31, 95%CI: 026-0.36, P＜0.001), as well as significant reductions in rate of progression (RR=0.41, 95%CI: 0.29-0.57, P＜0001), rate of leucopenia (RR=0.65, 95%CI: 0.57-0.75, P＜0.001), incidence rate of gastrointestinal reactions (RR=0.72, 95%CI: 059-088, P=0.001), and peripheral blood CD8+ T lymphocytes (MD=-4.68, 95% CI: -5.84 to -3.51, P＜0001). ConclusionJinlong capsules combined with Western medicine treatment has a marked clinical effect in the treatment of advanced primary liver cancer with few adverse events and thus holds promise for clinical application.
